Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17,013 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response.
Parker C, Tunariu N, Tovey H, Alonzi R, Blackledge MD, Cook GJR, Chua S, Du Y, Hafeez S, Murray I, Padhani AR, Staffurth J, Tree A, Stidwill H, Finch J, Curcean A, Chatfield P, Perry S, Koh DM, Hall E. Parker C, et al. Among authors: du y. JNCI Cancer Spectr. 2023 Oct 31;7(6):pkad077. doi: 10.1093/jncics/pkad077. JNCI Cancer Spectr. 2023. PMID: 37788117 Free PMC article. Clinical Trial.
Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT study.
Welsh L, Panek R, McQuaid D, Dunlop A, Schmidt M, Riddell A, Koh DM, Doran S, Murray I, Du Y, Chua S, Hansen V, Wong KH, Dean J, Gulliford S, Bhide S, Leach MO, Nutting C, Harrington K, Newbold K. Welsh L, et al. Among authors: du y. Radiat Oncol. 2015 May 15;10:112. doi: 10.1186/s13014-015-0415-7. Radiat Oncol. 2015. PMID: 25971451 Free PMC article. Clinical Trial.
The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with 18F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma.
Wong KH, Panek R, Welsh L, Mcquaid D, Dunlop A, Riddell A, Murray I, Du Y, Chua S, Koh DM, Bhide S, Nutting C, Oyen WJ, Harrington K, Newbold KL. Wong KH, et al. Among authors: du y. J Nucl Med. 2016 Dec;57(12):1843-1850. doi: 10.2967/jnumed.116.174433. Epub 2016 Jul 14. J Nucl Med. 2016. PMID: 27417648 Free article. Clinical Trial.
Systemic Radiotherapy of Bone Metastases With Radionuclides.
Murray I, Du Y. Murray I, et al. Among authors: du y. Clin Oncol (R Coll Radiol). 2021 Feb;33(2):98-105. doi: 10.1016/j.clon.2020.11.028. Clin Oncol (R Coll Radiol). 2021. PMID: 33353771 Free article. Review.
Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.
Denis-Bacelar AM, Chittenden SJ, Dearnaley DP, Divoli A, O'Sullivan JM, McCready VR, Johnson B, Du Y, Flux GD. Denis-Bacelar AM, et al. Among authors: du y. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):620-629. doi: 10.1007/s00259-016-3543-x. Epub 2016 Oct 21. Eur J Nucl Med Mol Imaging. 2017. PMID: 27770145 Free PMC article.
Molecular radiotheragnostics in prostate cancer.
Du Y, Dizdarevic S. Du Y, et al. Clin Med (Lond). 2017 Oct;17(5):458-461. doi: 10.7861/clinmedicine.17-5-458. Clin Med (Lond). 2017. PMID: 28974599 Free PMC article.
17,013 results
You have reached the last available page of results. Please see the User Guide for more information.